Submitted by moderatorj on Mon, 11/26/2012 - 22:46
Oculus to create subsidiary for anti-infective drug assets
Yahoo/TheFlyOnTheWall
Submitted by moderatorj on Wed, 11/14/2012 - 23:50
Oculus Innovative Sciences Completes Patient Enrollment in Study of Microcyn(R) Hydrogel in Management of Scars
Yahoo/GlobeNewswire
Submitted by moderatorj on Thu, 09/27/2012 - 22:36
Oculus Innovative Sciences Announces Publication of Results From Study of Microcyn(R) Technology-Based Antipruritic Hydrogel in Treatment of Atopic Dermatitis
Yahoo/GlobeNewswire
Submitted by moderatorj on Tue, 09/11/2012 - 22:39
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of U.S. Patent for Prevention and Treatment of Peritonitis With Microcyn(R) Technology
Yahoo/GlobeNewswire
Submitted by moderatorj on Thu, 09/06/2012 - 20:17
Oculus receives $5.1M licensing fee from More Pharma
TheFlyOnTheWall
Submitted by moderatorj on Mon, 08/06/2012 - 12:07
Oculus Innovative Sciences' CEO Discusses F1Q13 Results - Earnings Call Transcript
China Biotech In Review: Deals, Trials And Regulations
Seeking Alpha
Submitted by moderatorj on Tue, 07/10/2012 - 22:29
Oculus Innovative Sciences Receives Chinese SFDA Regulatory Approval of Microcyn(R) Hydrogel
Yahoo/GlobeNewswire
Submitted by moderatorj on Mon, 06/25/2012 - 23:14
AmDerma and Oculus Innovative Sciences Enter Into Multi-Country Agreement to Develop and Commercialize Novel Microcyn(R)-Based Drugs for Major Dermatological Conditions
Yahoo/GlobeNewswire